NCT04282031View on ClinicalTrials.gov

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Advanced Solid TumorHR+/HER2- Breast Cancer
Interventions
DRUG

BPI-1178

BPI-1178 once daily on Days 1 to 21 of a 28-day cycle

DRUG

Fulvestrant

Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and on Day 1 of Cycle 2 and beyond

DRUG

Letrozole

Letrozole 2.5 mg once daily of a 28-day cycle

DRUG

BPI-1178

BPI-1178 once daily of a 28-day cycle

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Beta Pharma (Suzhou) Co., Ltd.

INDUSTRY

NCT04282031 - A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer | Biotech Hunter | Biotech Hunter